Fujitsu is engaged in a comprehensive joint research agreement with National Cancer Center Japan on exploring ways that real-world data, including medical information from electronic records, can be leveraged to contribute to the development of new drugs, clinical trials, and preventive medicine in pharmaceutical companies.
Through this, Fujitsu intends to harness a wide range of information and analysis services by creating an anonymized personal health record scheme (PHR), which includes case study information and health information on patients visiting the National Cancer Center Hospital East.
Also, Fujitsu seeks to create a platform for providing pharmaceutical companies with data that can be used for drug development and preventive medicine.
Fujitsu will establish a new model to process medical information from electronic medical records into highly secure statistical data to improve the efficiency of clinical trials and supports active participation in international joint clinical trials by promoting the adaptation of clinical trial data in Japan to global standards.
Further, Fujitsu will work to improve the development speed and quality of pharmaceuticals and other products that promote the health of consumers. In turn, Fujitsu will play a role in resolving issues such as the time required for clinical trials and costs, create a variety of services that contribute to areas such as preventive medicine and individualized cancer medicine.
In recent years, real-world data has been attracting increased attention in the healthcare field, and it is beginning to be used in a wide range of fields globally — from drug approval applications to the development of medical devices and preventive medicine.
A variety of different data types are being used to these ends, ranging from patient electronic medical record information and medical examination information, to daily measurement data such as weight and body composition monitors, as well as vital information such as temperature and blood pressure that can be obtained from smart devices.